SCYNEXIS (SCYX)

• Market cap: $34.2M
• 1 day: 3.57%
• 5 days: 5.64%
• 1 month: 15.75%
• 3 months: 15.77%
• 6 months: -16.33%
• Year to date: -41.72%
• 1 year: -46.17%
• 5 years: -85.65%
• 10 years: -98.82%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Employees: 29

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

1.47% less ownership

Funds ownership: 29.78% [Q1] → 28.31% (-1.47%) [Q2]

5% less funds holding

Funds holding: 41 [Q1] → 39 (-2) [Q2]

33% less capital invested

Capital invested by funds: $11M [Q1] → $7.45M (-$3.6M) [Q2]

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K